Search clinical trials for: Overall response rate

Total 18474 results

Fujian Medical University

Recruiting

A Study on the Safety and Efficacy of the Combination of Candenizumab, Lenvatinib, and SOX Regimen in the Treatment of HER2 Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Patients

Overall Response Rate

China
The First Affiliated Hospital of Nanchang University
Shanghai Dengding BioAI Co.

Recruiting

Using Neoantigen Peptide Vaccine/Neoantigen-based DC to Treat Advanced Malignant Solid Tumors

Advanced Malignant Solid Tumors

China
Hospices Civils de Lyon

Recruiting

Predictive Clinical Features for Response to Adjuvant Immunotherapy in Stage II,III and IV Resected Melanoma (Mel-ImmAdj)

Melanoma

France
National Cancer Institute (NCI)

Recruiting

M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma

Colorectal Neoplasms | Colorectal Cancer | Cholangiocarcinoma | Bile Duct Cancer | Bile Duct Neoplasms | Metastatic Colorectal Cancer (Mcrc) | Intrahepatic Cholangiocarcinoma (Icc) | Intrahepatic Bile Duct Cancer

United States
Centre Leon Berard

Recruiting

A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments (ATEZOGIST)

Metastatic Gastrointestinal Stromal Tumor | Unresectable Gastrointestinal Stromal Tumor (GIST) | Locally Advanced Gastrointestinal Stromal Tumor (GIST)

France
Novartis Pharmaceuticals
Eckert & Ziegler Radiopharma GmbH

Recruiting

Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan

Prostate Cancer

Japan
Peking Union Medical College Hospital
Henan Cancer Hospital; Qilu Hospital of Shandong University; Beijing Tongren... and other collaborators

Recruiting

Phase II Study of Orelabrutinib Combined With PD-1 Inhibitor in Relapsed/Refractory Primary Central Nervous System Lymphoma

Primary Central Nervous System Lymphoma

China
Vaccinex Inc.
Merck Sharp & Dohme LLC

Recruiting

Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (KEYNOTE-B84)

Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)

United States
Centre Leon Berard

Recruiting

Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype (RAR-Immune)

Sarcoma

France
Centre Leon Berard

Recruiting

Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients (REGOMAIN)

Osteosarcoma | Bone Sarcoma

France
Lei Li

Recruiting

Combination of Nimotuzumab and Radiotherapy for Recurrent Uterine Cervical Squamous Carcinoma

Recurrent Cervical Carcinoma | Radiotherapy | Objective Response Rate | Overall Survival | Progression-free Survival | Epidermal Growth Factor Receptor | Nimotuzumab

China
Taproot Health

Recruiting

The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT)

Melanoma | Sarcoma | Kidney Cancer | Adenocarcinoma | Renal Cell Carcinoma | Cervical Cancer | Acute Myeloid Leukemia | Stomach Cancer | Breast Cancer | Head and Neck Neoplasms | Nasopharyngeal Carcinoma | Glioblastoma | Astrocytoma | Multiple Myeloma | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Small Bowel Cancer and other conditions

United States
Second Affiliated Hospital, School of Medicine,...

Recruiting

TILA-TACE in Treatment of Hepatocellular Carcinoma

Overall Survival | Tumor Response Rate

China
Peking Union Medical College Hospital
OrigiMed

Recruiting

Real-world Study for Patients With Advanced Hepatobiliary Tumors

Quality of Life | Objective Response Rate | Overall Survival | Progression-free Survival | Disease Control Rate | Duration of Response | Five-year Survival Rate

China
Regeneron Pharmaceuticals

Active, not recruiting

Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma

Relapsed and Refractory Multiple Myeloma (RRMM)

United States
NantCell, Inc.
National Cancer Institute (NCI)

Completed

QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma

Chordoma

United States
Acerta Pharma BV

Active, not recruiting

A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)

Glioblastoma Multiforme

United States
Novartis Pharmaceuticals

Active, not recruiting

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

China
University of Maryland, Baltimore

Active, not recruiting

Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

United States
Oncolytics Biotech
PrECOG, LLC.

Active, not recruiting

A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study

Breast Cancer Metastatic

United States
AbbVie

Completed

A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent). (VENICE II)

Chronic Lymphocytic Leukemia (CLL)

Argentina, Australia, Bulgaria, Hong Kong, Hungary, Mexico, New Zealand, Poland, Russian Federation, Taiwan
Wei Jiang
Wuzhou Red Cross Hospital; Laibin People's Hospital; Guangxi Naxishan Hospital; People's Hospital of Lingshan

Completed

Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Shandong Provincial Hospital

Unknown

Microwave Ablation in Combination With Camrelizumab Versus Camrelizumab in Metastatic Non-small-cell Lung Cancer (MWA in NSCLC)

NSCLC Stage IV

China
Lund University Hospital
Celgene; Janssen, LP; Nordic Lymphoma Group

Completed

A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma (PHILEMON)

Relapsed/Refractory Mantle Cell Lymphoma

Finland, Denmark, Sweden, Norway
M.D. Anderson Cancer Center
GlaxoSmithKline; Novartis

Completed

Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)

Leukemia

United States
Carlos Graux, MD, PhD
Celgene Corporation; Belgian Hematological Society

Completed

Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation.

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

Belgium
National Cancer Institute (NCI)

Terminated

Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer

Renal Cancer | Birt-Hogg-Dube Syndrome

United States
Centre Leon Berard

Terminated

BENdamustine at Elevated Dose for Relapsed Follicular Lymphoma in Intensification Therapy and Transplantation (BENEFIT) (BENEFIT)

Follicular Lymphoma

France
Peking University People's Hospital
Peking University; Northwestern University; University of Chicago

Unknown

Epigenetic Biomarker for Osteosarcoma

Histologic Response (Tumor Necrosis Rate) | Objective Response Rate for Neoadjuvant Chemotherapy, ORR | Progression-free Survival, PFS | Overall Survival, OS

China
National Cancer Institute (NCI)

Completed

Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma

Melanoma

United States
University of Arkansas

Withdrawn

UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib

Multiple Myeloma

United States
Centre Leon Berard
GlaxoSmithKline

Completed

Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST) (PAZOGIST)

GIST

France
Centre Leon Berard

Withdrawn

Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE) (PENILANE)

Squamous Cell Carcinoma of the Penis

France
University of Arkansas

Withdrawn

A Single Agent Study to Evaluate the Overall Response Rate, Safety and Tolerability of Orally Administered Vemurafenib

Multiple Myeloma

United States
Centre Leon Berard
National Cancer Institute, France

Terminated

Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (AKTIL)

Diffuse Large B Cell Lymphoma

France
Fudan University

Completed

Continuous Infusion of FU Combined With Epirubicin and Oxaliplatin in Patients With A/MGC

Gastric Cancer

China
Fudan University

Completed

Apatinib Versus Placebo as a Third Line Treatment in Patients With Advanced or Metastatic Gastric Cancer

Gastric Carcinoma

China
Fudan University

Completed

Epirubicin Cisplatin and Fluorouracil (FU) Combined With Endostar in Patients With Advanced or Metastatic Gastric Cancer

Gastric Cancer

China
Shanghai CP Guojian Pharmaceutical Co., Ltd.

Completed

Study for HER2-Overexpressed MBC Patients Treated by Cipterbin® Plus vinorelbinE (HOPES)

Adverse Events | Progress-free Survival | Overall Response Rate
Fudan University

Unknown

Study of Endostatin Combined With Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer Patients

Carcinoma, Non-Small-Cell Lung

China
Fudan University

Unknown

Sorafenib and FOLFIRI Regimen in 2nd Colorectal Cancer (CRC) After Failure of Oxaliplatin Treatment

Colorectal Neoplasms

China
Wolfson Medical Center

Unknown

Combined Treatment With Fresh Frozen Plasma and Rituximab (Mabthera) in Patients With Advanced Refractory Chronic Lymphocytic Leukemia

Advanced Refractory Chronic Lymphocytic Leukemia

Israel
Fudan University

Suspended

Combination of Capecitabine and Oxaliplatin in Patients With Relapsed or Refractory Gastric Cancer

Gastric Cancer

China
Fudan University

Completed

Study of Cetuximab to Treat Gastric Cancer (STAGE)

Gastric Cancer

China
Fudan University

Terminated

Sorafenib as a Second Line Treatment in Patients With Advanced or Metastatic Gastric Cancer

Gastric Cancer

China
Chimei Medical Center
E-DA Hospital

Not yet recruiting

Clinical Outcomes Of Mega-dosage Supplementations Of Cholecalciferol In Critically Ill Patients With Sepsis (MDC-S)

Sepsis | Critically Ill | Critical Care | Mortality Rate
University Hospital, Lille

Not yet recruiting

Evaluation of Autonomic Nervous System Changes in Response to Stimulation by Sacral Neuromodulation (ESTIME)

Sacral Neuromodulation | Bladder Hyperactivity
Changhai Hospital
Shanghai 10th People's Hospital; Ruijin Hospital; Shanghai Ninth People's Hospital... and other collaborators

Not yet recruiting

Real-World Clinical Study on the Efficacy of Vibrating Capsule (Vibrabot Capsule) for Chronic Functional Constipation (RWS-VC)

Clinical Study | Chronic Functional Constipation

China
Assistance Publique - Hôpitaux de Paris
Institut Pasteur

Recruiting

Physiology and Pathologies Linked to Human Splenic Function : Direct and Ex-vivo Perfusion Explorations (SPLEENVIVO)

Splenectomy

France
Henan Cancer Hospital

Not yet recruiting

Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer

Breast Cancer | HER2-positive Breast Cancer

China

Search clinical trials for: Overall response rate

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Australia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations